Significance of 5-fluorouracil-related enzyme activities in predicting sensitivity to 5-fluorouracil in bladder carcinoma

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 1001-1008

  Furuse, Hiroshi ^a   Hirano, Yasuhiro ^a   Harada, Masaki ^a   Liu, Hong Ming ^a   Aoki, Takahiro ^a   Kurita, Yutaka ^a   Mugiya, Soichi ^a   Ushiyama, Tomomi ^a   Ozono, Seiichiro ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

4 dihydroxypyridine; 5 chloro 2; 5 fluorouracil; Bladder urothelial carcinoma; Dihydropyrimidine dehydrogenase; Orotate phosphoribosyl transferase

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; OROTATE PHOSPHORIBOSYLTRANSFERASE; THYMIDINE PHOSPHORYLASE;

AGED; ARTICLE; BLADDER CARCINOMA; CHEMOSENSITIVITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CASE-CONTROL STUDIES; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; OROTATE PHOSPHORIBOSYLTRANSFERASE; PREDICTIVE VALUE OF TESTS; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 64949195410     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Sternberg CN, Donat SM, Bellmunt J, Millikan RE, Stadler W, De Mulder P, Sherif A, von der Maase H, Tsukamoto T and Soloway MS: Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 69(Suppl 1A): 62-79,2007.
2. Sylvester RJ, van der Meijden AP and Lamm DL: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a combined analysis of the published results of randomized clinical trials. J Urol 168: 1964-1970, 2002.
3. Hinotsu S, Akaza H, Ohashi Y and Kotake T: Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer 86: 1818-182, 1999.
4. Kubota Y, Noguchi S and Hosaka M: UFT in bladder cancer. Oncology 13(7 suppl 3): 112-115, 1999.
5. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lunz HJ, Leichman CG, Leichman L, Diasio RB and Danenberg PV: Colorectal tumors responding to 5-Fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6: 1322-1327, 2000.
6. Ando T, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Sugito N, Mori R, Ogawa R, Katada T and Fujii Y: Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines. Dis Esophagus 21: 15-20, 2008.
7. Ichikawa W, Uetake H, Shirota Y, Yamada H, Takahashi T, Nihei Z, Sugihara K, Sasaki Y and Hirayama R: Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 89: 1486-1492, 2003.
8. Takechi T, Fujioka A, Matsushima E and Fukushima M: Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer 38: 1271-1277, 2002.
9. Fujiwara H, Terashima M, Irinoda T, Takagane A, Abe K, Nakaya T, Yonezawa H, Oyama K, Takahashi M, Saito K, Takechi T, Fukushima M and Shirasaka T: Superior antitumor activity of S-l in tumours with a high dihydropyrimidine dehydrogenase activity. Eur J Cancer 39: 2387-2394, 2003.
10. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A and Arai K; ACTS-GC Group: Adjuvant chemotherapy for gastric cancer with S-l, an oral fluoropyrimidine. N Engl J Med 357: 1810-1820, 2007.
11. Mochiki E, Ohno T, Kamiyama Y, Aihara R, Haga N, Ojima H, Nakamura J, Ohsawa H, Nakabayashi T, Takeuchi K, Asao T and Kuwano H; North Kanto Gastric Cancer Study Group: Phase I/II study of S-l combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer. Br J Cancer 95: 1642-1647, 2006.
12. Laskin JD, Evans RM, Slocum HK, Burke D and Hakala MT: Basis for natural variation in sensitivity to 5-fluorouracil in mouse and human cells in culture. Cancer Research 39: 383-390, 1979.
13. Katsumata K, Tomioka H, Sumi T, Yamashita S, Takagi M, Kato F, Nakamura R, Koyanagi Y, Aoki T and Kato K: Correlation between clinicopathologic factors and kinetics of metabolic enzymes for 5-fluorouracil given to patients with colon carcinoma by two different dosage regimens. Cancer Chemother Pharmacol 51: 155-160, 2003.
14. Lowry OH, Rosebrough NJ, Fair AL and Randall RJ: Protein measurement with the folin phenol reagent. J Biol Chem 193: 265-275, 1951.
15. Mori K, Hasegawa M, Nishida M, Toma H, Fukuda M, Kubota T, Nagasue N, Yamana H, Hirakawa-YS Chung K, Ikeda T, Takasaki K, Oka M, Kameyama M, Toi M, Fujii H, Kitamura M, Murai M, Sasaki H, Ozono S, Makuuchi H, Shimada Y, Onishi Y, Aoyagi S, Mizutani K, Ogawa M, Nakao A, Kinoshita H, Tono T, Imamoto H, Nakashima Y and Manabe T: Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol 17: 33-38, 2000.
16. Nishida M, Hino A, Mori K, Matsumoto T, Yoshikubo T and Ishitsuka H: Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol Pharm Bull 19(11): 1407-1411, 1996.
17. Hoffman RM: In vitro sensitivity assays in cancer: a review, analysis, and prognosis. J Clin Lab Anal 5(2): 133-143, 1991.
18. Hirano Y, Ushiyama T, Suzuki K and Fujita K: Clinical application of an in vitro chemosensitivity test, the histoculture drug response assay, to urological cancers: wide distribution of inhibition rates in bladder cancer and renal cell cancer. Urol Res 27: 483-488, 1999.
19. Vescio RA, Connors KM, Kubota T and Hoffman RM: Correlation of histology and drug response of human tumors grown in native-state three-dimensional histoculture and in nude mice. Proc Natl Acad Sci USA 88: 5163-5166, 1991.
20. Peters GJ, van Groeningen CJ, Laurensse EJ and Pinedo HM: Comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa. Cancer 68(9): 1903-1909, 1991.
21. Fukushima M, Nomura H, Murakami Y, Shirasaka T and Aiba K: Estimation of pathways of 5-fluorouracil anabolism in human cancer cells in vitro and in vivo (in Japanese). Gan to Kagaku Ryoho 23(6): 721-731, 1996.
22. Sakurai Y, Kamoshida S, Furuta S, Sunagawa R, Inaba K, Isogaki J, Komori Y, Uyama I and Tsutsumi Y: Levels and expressions of orotate phosphoribosyltransferase in gastric carcinoma and normal gastric mucosa tissues. Gastric cancer 10: 234-240,2007.
23. Isshi K, Sakuyama T, Gen T, Nakamura Y, Kuroda T, Katuyama T and Maekawa Y: Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU. Int J Clin Oncol 7: 335-342, 2002.
24. Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K, Usuki K, Takaku F, Risau W and Heldin CH: Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 338: 557-56, 1989.
25. Mizutani Y, Okada Y and Yoshida O: Expression of platelet-derived endothelial cell growth factor in bladder carcinoma. Cancer 79: 1190-1194, 1997.
26. Hirano Y, Kageyama S, Ushiyama T, Suzuki K and Fujita K: Clinical significance of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in transitional cell cancer. Cancer Chemother Pharmacol 51: 29-35, 2003.
27. Hirano Y, Takayama T, Kageyama S, Ushiyama T, Suzuki K and Fujita K: Thymidine phosphorylase activity in renal cell carcinoma: relationship between histological parameter and chemosensitivity to fluorouracil-related drugs. Urol Res 30: 112-115,2002.
28. Hirano Y, Kageyama S, Ushiyama T, Suzuki K and Fujita K: Thymidine phosphorylase activity in transitional cell cancer: relation to histological parameters and chemosensitivity to fluorouracil- related drugs. Anticancer Res 20(6B): 4315-4318, 2000.
29. Mizutani Y, Wada H, Fukushima M, Yoshida O, Ukimura O, Kawauchi A and Miki T: The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer. Eur J Cancer 37: 569-575,2001.
30. Furuse H, Hirano Y, Harada M, Mugiya S, Ushiyama T, Suzuki K and Ozono S: Orotate Phosphoribosyl transferase in bladder cancer. Gan to Kagaku Ryoho 31: 1431-1433,2004 (in Japanese).
31. Mizutani Y, Wada H, Fukushima M, Yoshida O, Nakanishi H, Li YN and Miki T: Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma. Cancer 100: 723-731,2004.
32. Mizutani Y, Wada H, Yoshida O, Fukushima M, Kawauchi A, Nakao M and Miki T: The significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor activity in renal cell carcinoma. Cancer 98: 730-736, 2003.